Sector News

Valeant makes offer for Zoetis, sources tell WSJ, but is it serious?

June 26, 2015
Life sciences
If you want to run with the big dogs of pharma, then you can’t just sit on the porch and bark about being in animal health. That is what rapidly expanding Valeant ($VRX) apparently decided, having approached Zoetis ($ZTS) about a buyout, sources told the Wall Street Journal. Rumors of a possible deal, which have been bouncing back and forth between Wall Street and the industry for weeks, set off buying, with Zoetis shares closing up 11% Thursday at an all-time high of $55.38.
 
Shares then fell about 10% on Friday when a CNBC commentator claimed the offer was made but is unlikely to be pursued.
 
No price was mentioned, but Zoetis has a market cap of about $25 billion. The timing of the reported offer is also pivotal, the newspaper said. Zoetis was spun off from Pfizer ($PFE) in 2013, and Wednesday was the first day that the animal health company could strike a deal without incurring a big tax hit tied to the spinoff.
 
Earlier this year, Valeant CEO J. Michael Pearson tried to quash rumors he was going to make a run at the world’s largest animal health company, but a lot of folks weren’t buying it. He has an indirect line to the business through activist investor Bill Ackman, who owns 5.7% of Valeant and 8% of Zoetis. Ackman helped Pearson and Valeant last year in its failed effort to buy out Botox maker Allergan ($AGN). Since Valeant got outbid for Allergan by Actavis, Zoetis has repeatedly been raised as a good fallback play.
 
And Ackman has been priming Zoetis for a buyer, pushing it to trim down and get its costs down. Last month the company rolled over for his demands, saying it would lay off 25% of its workforce, about 2,500 employees, and close 10 manufacturing plants. The effort would cut $300 million in operating costs and raise its adjusted operating margin to 34% from 25% in 2017, the company said.
 
Pearson has kept his buyout skills sharpened since Valeant’s failed run at Allergan. In February, Valeant nailed two deals valued at $10.5 billion. It first picked up prostate cancer vaccine Provenge from bankrupt Dendreon for $400 million to expand its position in oncology, then turned around and offered Salix Pharmaceuticals $10.1 billion to get into the rapidly growing GI market.
 
By Eric Palmer
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach